Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | CNR2 | P34972 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14411395 | 0.91 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2HRH3DRD2DRD3 | |
| SCHEMBL5452543 | 0.88 | ATM (0.52) | ALDH1A1SMN1; SMN2DRD2DRD3CNR1 | |
| SCHEMBL5453001 | 0.83 | CNR2 (0.47) | ALDH1A1SMN1; SMN2CNR1CNR2 | |
| SCHEMBL5446909 | 0.83 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2TSHRL3MBTL1MAOB | |
| SCHEMBL5446836 | 0.82 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2TSHRL3MBTL1MAOB | |
| SCHEMBL5455205 | 0.82 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2TSHRL3MBTL1MAOB | |
| SCHEMBL5446902 | 0.82 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2TSHRL3MBTL1MAOB | |
| SCHEMBL5476485 | 0.81 | HRH3 (0.46) | ALDH1A1SMN1; SMN2HRH3MAOB | |
| SCHEMBL5446808 | 0.80 | IDO1 (0.51) | ALDH1A1HRH3DRD3L3MBTL1KCNA5 | |
| SCHEMBL5448848 | 0.80 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2TSHRL3MBTL1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | ALDH1A1 2963/4885SMN1; SMN2 1701/4885HRH3 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.